Clinical Trial Update: Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intercalated PamCis with Gefitinib or with placebo as first-line therapy for never-smoker patients with non-small cell lung cancer, spe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• PamCis

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Non Small Cell Lung Cancer, Adenocarcinoma | Phase 2 | Status: UNKNOWN